Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARCT

ARCT - Arcturus Therapeutics Holdings Inc Stock Price, Fair Value and News

$7.39-0.07 (-0.94%)
Market Closed

58/100

ARCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

58/100

ARCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.52

Target 3M

$7.76

Target 6M

$8.01

ARCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARCT Price Action

Last 7 days

1.7%

Last 30 days

20.0%

Last 90 days

-23.3%

Trailing 12 Months

-54.9%

ARCT RSI Chart

ARCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARCT Valuation

Market Cap

210.0M

Price/Earnings (Trailing)

-3.15

Price/Sales (Trailing)

2.15

EV/EBITDA

-0.47

Price/Free Cashflow

-3.58

ARCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.52

Target 3M

$7.76

Target 6M

$8.01

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

97.6M

Rev. Growth (Yr)

-58.84%

Rev. Growth (Qtr)

-39.4%

ARCT Earnings

Earnings (TTM)

-66.7M

Earnings Growth (Yr)

-94.81%

Earnings Growth (Qtr)

-46.49%

ARCT Profitability

EBT Margin

-68.35%

Return on Equity

-29.71%

Return on Assets

-23.63%

Free Cashflow Yield

-27.93%

ARCT Investor Care

Shares Dilution (1Y)

4.89%

Diluted EPS (TTM)

-2.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025143.7M122.1M97.6M0
2024124.5M163.9M160.4M152.3M
2023281.0M264.5M296.2M166.8M
202215.5M40.6M51.5M206.0M
20219.0M8.7M8.8M12.4M
202019.1M11.3M10.3M9.5M
201917.0M18.3M19.5M20.8M
201800015.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arcturus Therapeutics Holdings Inc

ARCT
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://arcturusrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES170

Arcturus Therapeutics Holdings Inc Frequently Asked Questions

ARCT is the stock ticker symbol of Arcturus Therapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Arcturus Therapeutics Holdings Inc is 209.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ARCT's fair value in chart for subscribers.

The fair value guage provides a quick view whether ARCT is over valued or under valued. Whether Arcturus Therapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Arcturus Therapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARCT.

As of Wed Jan 28 2026, ARCT's PE ratio (Price to Earnings) is -3.15 and Price to Sales (PS) ratio is 2.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARCT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Arcturus Therapeutics Holdings Inc has provided -0.146 (multiply by 100 for percentage) rate of return.